LMR Partners’s Kura Oncology KURA Stock Holding History

LMR Partners’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-11,600	Closed	-$162K	–	1289
2021 Q4	$162K	Sell	11,600 -26,860	-70%	-$435K	﹤0.01%	1090
2021 Q3	$720K	Buy	+38,460	New	+$725K	0.01%	718

Other funds holding KURA

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

AWA

Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

LMR Partners's KURA Position: Q1 2022 in Review

LMR Partners sold out of Kura Oncology (KURA) in Q1 2022, closing a stake of 11,600 shares — an estimated $162K sold.

LMR Partners first reported a position in KURA in Q3 2021 and held it in 2 quarters. The position peaked at $720K in Q3 2021. 152 funds tracked by Wall St. Rank hold KURA as of Q1 2022.

LMR Partners reported no remaining Kura Oncology position as of Q1 2022 after selling out during the quarter.
LMR Partners sold 11,600 Kura Oncology shares in Q1 2022, an estimated $162K.
LMR Partners first reported a position in Kura Oncology in Q3 2021 and held it in 2 quarters.
LMR Partners's Kura Oncology position peaked at $720K in Q3 2021.
152 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2022.

Based on LMR Partners's 13F filing for Q1 2022, filed 16 May 2022.